Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

ABSTRACT:

SUBMITTER: Powles T 

PROVIDER: S-EPMC8442414 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature